SR-9009 (1379686-30-2) is an agonist at nuclear receptor Rev-ErbA¹. Greatly diminishes VILI-induced lung edema, inflammatory cell infiltration and TNFα production in a rat lung injury model². SR-9009 suppresses atherosclerosis in a mouse model³.  Specifically lethal to cancer cells and oncogene-induced senescent cells with no effect on the viability of normal cells or tissues.⁴ Disrupts pain associated with osteoarthritis by reducing BMAL1 expression in bmal1f/fNav1.8CreERT mice.⁵

References/Citations
1) Solt et al. (2012) Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists; Nature, 485 62
2) Li et al. (2014) A study on circadian rhythm disorder of rat lung tissue caused by mechanical ventilation induced lung injury; Int.Immunopharmacol. 18 249
3) Sitaula et al. (2015) Suppression of atherosclerosis by synthetic REV-ERB agonist; Biochem. Biophys. Res. Commun., 460 566
4) Sulli et al. (2018) Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence; Nature, 553 351
5) Das et al. (2018) Pharmacological targeting of the mammalian clock reveals a novel analgesic for osteoarthritis-induced pain; Gene 655 1